Assays measuring methylation of MAL, TIG1, HSPB1, CCND2, and DPYS have potential to accurately stratify early prostate cancers and thereafter to manage affected patients in a biologically appropriate manner. The gene discussed is CCND2; the disease is prostate cancer.